These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 21149662)

  • 1. Dose finding study for the use of subcutaneous recombinant interleukin-2 to augment natural killer cell numbers in an outpatient setting for stage 4 neuroblastoma after megatherapy and autologous stem-cell reinfusion.
    Ladenstein R; Pötschger U; Siabalis D; Garaventa A; Bergeron C; Lewis IJ; Stein J; Kohler J; Shaw PJ; Holter W; Pistoia V; Michon J
    J Clin Oncol; 2011 Feb; 29(4):441-8. PubMed ID: 21149662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
    Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.
    Matthay KK; Tan JC; Villablanca JG; Yanik GA; Veatch J; Franc B; Twomey E; Horn B; Reynolds CP; Groshen S; Seeger RC; Maris JM
    J Clin Oncol; 2006 Jan; 24(3):500-6. PubMed ID: 16421427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin's lymphoma patients after autologous bone marrow transplantation.
    Lauria F; Raspadori D; Ventura MA; Rondelli D; Zinzani PL; Gherlinzoni F; Miggiano MC; Fiacchini M; Rosti G; Rizzi S; Tura S
    Bone Marrow Transplant; 1996 Jul; 18(1):79-85. PubMed ID: 8831999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose systemic interleukin-2 therapy in stage IV neuroblastoma for one year after autologous bone marrow transplantation: pilot study.
    Pardo N; Martí F; Fraga G; Illa J; Badell I; Peiró M; Bertran E; García J; Rueda F; Cubells J
    Med Pediatr Oncol; 1996 Dec; 27(6):534-9. PubMed ID: 8888813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation.
    Martí F; Pardo N; Peiró M; Bertran E; Amill B; García J; Cubells J; Rueda F
    Exp Hematol; 1995 Dec; 23(14):1445-52. PubMed ID: 8542930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tandem high-dose chemotherapy and autologous stem cell rescue in patients over 1 year of age with stage 4 neuroblastoma.
    Sung KW; Lee SH; Yoo KH; Jung HL; Cho EJ; Koo HH; Lee SK; Kim J; Lim DH; Suh YL; Kim DW
    Bone Marrow Transplant; 2007 Jul; 40(1):37-45. PubMed ID: 17468771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy with low-dose recombinant interleukin 2 after high-dose chemotherapy and autologous stem cell transplantation in neuroblastoma.
    Pession A; Prete A; Locatelli F; Pierinelli S; Pession AL; Maccario R; Magrini E; De Bernardi B; Paolucci P; Paolucci G
    Br J Cancer; 1998 Aug; 78(4):528-33. PubMed ID: 9716039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission.
    Stone RM; DeAngelo DJ; Janosova A; Galinsky I; Canning C; Ritz J; Soiffer RJ
    Am J Hematol; 2008 Oct; 83(10):771-7. PubMed ID: 18756547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo.
    Redlinger RE; Mailliard RB; Lotze MT; Barksdale EM
    J Pediatr Surg; 2003 Mar; 38(3):301-7; discussion 301-7. PubMed ID: 12632339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I-II study of interleukin-2 after high-dose chemotherapy and autologous bone marrow transplantation in poorly responding neuroblastoma.
    Valteau-Couanet D; Rubie H; Meresse V; Farace F; Brandely M; Hartmann O
    Bone Marrow Transplant; 1995 Oct; 16(4):515-20. PubMed ID: 8528166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized controlled multicenter study comparing recombinant interleukin 2 (rIL-2) in conjunction with recombinant interferon alpha (IFN-alpha) versus no immunotherapy for patients with malignant lymphoma postautologous stem cell transplantation.
    Nagler A; Berger R; Ackerstein A; Czyz JA; Diez-Martin JL; Naparstek E; Or R; Gan S; Shimoni A; Slavin S
    J Immunother; 2010 Apr; 33(3):326-33. PubMed ID: 20445353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant subcutaneous interleukin-2 in patients with resected renal cell carcinoma: a pilot study.
    Majhail NS; Wood L; Elson P; Finke J; Olencki T; Bukowski RM
    Clin Genitourin Cancer; 2006 Jun; 5(1):50-6. PubMed ID: 16859579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma.
    Whitehead RP; Ward D; Hemingway L; Hemstreet GP; Bradley E; Konrad M
    Cancer Res; 1990 Oct; 50(20):6708-15. PubMed ID: 2208137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Value of prognostic factors in the Austrian A-NB87 Neuroblastoma Study].
    Ladenstein R; Ambros PF; Urban C; Ambros IM; Fink FM; Zoubek A; Grienberger H; Schmitt K; Kerbl R; Horcher E; Amann G; Höfler G; Heinzl H; Gadner H; Mutz I
    Klin Padiatr; 1996; 208(4):210-20. PubMed ID: 8926686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors.
    Bosly A; Guillaume T; Brice P; Humblet Y; Staquet P; Doyen C; Chatelain B; Franks CR; Gisselbrecht C; Symann M
    Exp Hematol; 1992 Sep; 20(8):962-8. PubMed ID: 1354620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The incidence of hearing impairment after successful treatment of neuroblastoma.
    Simon T; Hero B; Dupuis W; Selle B; Berthold F
    Klin Padiatr; 2002; 214(4):149-52. PubMed ID: 12165893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity.
    Goldstein D; Sosman JA; Hank JA; Weil-Hillman G; Moore KH; Borchert A; Bechhofer R; Storer B; Kohler PC; Levitt D
    Cancer Res; 1989 Dec; 49(23):6832-9. PubMed ID: 2819723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dose-intensive approach (NB96) for induction therapy utilizing sequential high-dose chemotherapy and stem cell rescue in high-risk neuroblastoma in children over 1 year of age.
    Monnereau-Laborde S; Munzer C; Valteau-Couanet D; Ansoborlo S; Coze C; Chastagner P; Rubie H; Demeocq F; Stephan JL; Hartmann O; Perel Y
    Pediatr Blood Cancer; 2011 Dec; 57(6):965-71. PubMed ID: 21744481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
    Khan KD; Emmanouilides C; Benson DM; Hurst D; Garcia P; Michelson G; Milan S; Ferketich AK; Piro L; Leonard JP; Porcu P; Eisenbeis CF; Banks AL; Chen L; Byrd JC; Caligiuri MA
    Clin Cancer Res; 2006 Dec; 12(23):7046-53. PubMed ID: 17145827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.